VIDAS® Chikungunya panel

2 automated assays for accurate diagnosis

The VIDAS® Chikungunya panel includes 2 immunoassays recommended by international guidelines to detect anti-chikungunya IgM and IgG antibodies at different phases of the disease.

  • Easy access to automation
  • Cost-effective solution, adapted to resource-limited settings
  • Excellent performance
Add to your selection

Do you need more information?

Transmitted to humans through the bites of infected mosquitoes, chikungunya virus (CHIKV) was first identified in Tanzania in 1952. Over the last two decades it has spread across the world to more than 100 countries, causing regular outbreaks in Asia and Africa, massive outbreaks in the Americas, and more sporadic and clustered cases in Europe.

As symptoms of chikungunya overlap with those of other mosquito-borne diseases, such as dengue and malaria, differential diagnosis in endemic areas is essential for optimized patient management. The VIDAS® CHIKUNGUNYA panel offers a complete solution for rapid and reliable confirmation of chikungunya infection.

Detection from acute to chronic disease

Recommended diagnostic methods(1)

3 specific chikungunya biomarkers are expressed after infection:

  • The presence of virus in the blood (viremia) can be detected early in the course of infection, and up to 7-10 days after the first symptoms.
  • Anti-chikungunya IgM antibodies are generally detectable 5-7 days after the contamination. It is classically admitted that they persist for several weeks, up to 3 months. However, it has been demonstrated that they can be detected in the blood of infected people up to more than one year after the acute phase.
  • Anti-chikungunya IgG antibodies are detectable a few days after IgM appearance, 7-10 days after the contamination, and can persist for years.

2 complementary tests

The VIDAS® CHIKUNGUNYA panel offers 2 complementary tests for accurate detection of the disease from the acute to the chronic phase:

  • VIDAS® Anti-CHIKUNGUNYA IgM: Early serological response
  • VIDAS® Anti-CHIKUNGUNYA IgG: Presence of specific immunity

Reliable and clear-cut results

VIDAS® Anti-CHIKUNGUNYA IgM VIDAS® Anti- CHIKUNGUNYA IgG
Immunocapture allows excellent performance(2) No cross reactivity with dengue, Zika, yellow fever and SARS-COV-2(2)
High sensitivity on follow-up of CHIKV positive patients: 100% (11-21 days) (2)

 

Developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC)

Accessible to a wide range of labs

The VIDAS® CHIKUNGUNYA panel provides an easy-to-use, flexible and cost-effective solution for automated chikungunya diagnosis.

  • Independent assays
  • Ready-to-use, single-dose tests
  • 24/7 availability
  • Just load & go
  • Objective result interpretation
  • Small, all-inclusive kits with long shelf life The VIDAS® CHIKUNGUNYA tests can be performed on all VIDAS® benchtop immunoanalyzers, trusted around the world for their robustness and reliability.

References

  1. Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P et al: French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect 2015, 45(7):243-263.
  2. VIDAS® Anti-CHIKUNGUNYA IgM and IgG package inserts

 

VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).

  VIDAS® Anti-CHIKUNGUNYA IgM VIDAS® Anti-CHIKUNGUNYA IgG
Reference 423229-30 / 423229 423230-30 / 423230
Tests / kit 30 / 60 30 / 60
Sample type Serum Serum
Calibration frequency Only 56 days Only 56 days
Shelf life 12 months 12 months

 

VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).

International Guidelines

  • PAHO – WHO recommendation

 

Useful Links

 

VIDAS® Anti-CHIKUNGUNYA IgM&IgG developed with the contribution of the United States National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC).

Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics